

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Olivier MEYER) Group Art Unit: Unassigned
Application No.: Unassigned) Examiner: Unassigned
Filed: June 14, 2001)
For: COMBINATION PRODUCT)
INTENDED FOR CARRYING OUT)
A CYTOTOXIC TREATMENT, IN)
PARTICULAR AN ANTITUMOUR)
TREATMENT, IN A MAMMAL)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

IN THE CLAIMS:

Kindly replace claims 19-26 as follows.

19. (Amended) The combination product of Claim 1, wherein said nucleic acid
(i) is a recombinant vector of plasmid or viral origin.

20. (Amended) The combination product of Claim 1, wherein it is formulated in
a vehicle which is pharmaceutically acceptable.

21. (Amended) Complex comprising at least one nucleic acid (i) containing a sequence encoding a polypeptide of interest, at least one phospholipid (ii) of interest, a substance (iii) which associates with nucleic acids and, optionally, an adjuvant (v), wherein said phospholipid of interest (ii) is as described in claim 1.

22+ are non-elected claims
22. (Amended) A method for treating the human or animal body comprising administering an effective amount of the combination product of claim 1 to a human or animal in need of such treatment.

23. (Amended) The method according to Claim 22, wherein the treatment is an antitumour and/or antimetastatic treatment.

24. (Amended) The method according to Claim 22, wherein said phospholipid of interest (ii) is administered simultaneously with the nucleic acid (i).

25. (Amended) The method according to claim 22, wherein said combination product or said complex is administered intratumorally or peritumorally.

26. (Amended) The method according to Claim 21, for simultaneously introducing a nucleic acid sequence (i) and a phospholipid (ii) into a cell.